Pelthos Therapeutics (PTHS) EBITDA Margin (2025 - 2026)
Pelthos Therapeutics (PTHS) posted EBITDA Margin of 114.72% for Q2 2026, up 4.41% on a QoQ basis from 120.01% in Q1 2026.
Powered by 
Analysis
Pelthos Therapeutics (PTHS) EBITDA Margin (2025 - 2026) Analysis & Trends
Pelthos Therapeutics has reported EBITDA Margin for 2 years, with the latest figure at 114.72% in Q2 2026.
- On a quarterly basis, EBITDA Margin changed N/A year-over-year to 114.72% in Q2 2026; TTM through Jun 2026 was 131.44%, a N/A change from a year earlier, with the FY2025 full-year figure at 193.09%, changed N/A from the prior year.
- EBITDA Margin was 114.72% for Q2 2026 at Pelthos Therapeutics, up from 120.01% in the prior quarter.
- The five-year high for EBITDA Margin was 114.72% in Q2 2026, with the low at 207.43% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.22 Bn | 620.47 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 446.22 Bn | 439.65 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 357.04 Bn | 349.90 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 268.38 Bn | 260.69 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 156.32 Bn | 144.62 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 52.23 Bn | 44.85 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 43.18 Bn | 43.18 Bn | - | - |
| 8 | Incyte | 24.85 Bn | 20.31 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 21.29 Bn | 18.62 Bn | 683.80 Mn | 42.23% |
| 10 | Pelthos Therapeutics | 80.38 Mn | 55.82 Mn | 21.23 Mn | -114.72% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -114.72% |
| Mar 31, 2026 | -120.01% |
| Dec 31, 2025 | -131.99% |
| Sep 30, 2025 | -207.43% |